Survival Rate for Completely Excised Poorly Differentiated Squamous Cell Carcinoma of the Aural Antitragus with Adjuvant Radiotherapy
For a completely excised poorly differentiated squamous cell carcinoma of the aural antitragus treated with surgery plus adjuvant radiotherapy, you can expect a 5-year overall survival rate of approximately 64-86%, with disease-free survival around 47-58%.
Evidence-Based Survival Data
The most relevant survival data comes from studies specifically examining external auditory canal and auricular squamous cell carcinomas treated with combined modalities:
Overall Survival Rates
- 5-year overall survival: 63.5-70.7% for external auditory canal SCC treated with curative intent radiotherapy (adjuvant or definitive) 1, 2
- 5-year survival: 64-86% specifically for auricular squamous cell carcinoma, with the higher rate (86%) seen in early-stage disease 3
- Surgery plus adjuvant radiotherapy demonstrates superior outcomes compared to radiotherapy alone or salvage approaches 4, 1
Disease Control Rates
- 5-year event-free survival: 57.8% in combined treatment approaches 1
- 5-year disease-free survival: 47.4% across all stages 2
- Local control rate: 100% when combining surgery with adjuvant radiotherapy, compared to only 67% with surgery alone 3
Critical Prognostic Factors That Modify These Rates
Your patient's survival will be significantly influenced by:
Favorable Factors Present in Your Case:
- Clear surgical margins - dramatically improves outcomes
- No clinically evident nodal disease - absence of lymph node involvement is strongly prognostic
- No distant metastases - critical for favorable prognosis
- Adjuvant radiotherapy use - associated with better overall survival (HR 0.47,95% CI: 0.34-0.65) 5
Concerning Factor:
- Poor differentiation - this is a high-risk feature that justifies the adjuvant radiotherapy approach 6
Treatment Approach Validation
The combination of complete surgical excision followed by adjuvant radiotherapy is the optimal evidence-based approach for this high-risk lesion 6, 1. The guideline explicitly states that "primary cSCC with concerning perineural invasion or otherwise at high risk for regional or distant metastasis may be considered for adjuvant radiation therapy to the local tumor site following surgical treatment" 6.
Why This Combination Works:
- Adjuvant radiotherapy provides lower recurrence rates (OR 0.56,95% CI: 0.36-0.85) 5
- Longer disease-free survival (OR 2.17,95% CI: 1.23-3.83) 5
- Longer overall survival (OR 2.94,95% CI: 1.75-4.91) 5
Pattern of Failure to Monitor
Local recurrence is the predominant failure pattern (40.4% of failures), while regional nodal failure is uncommon (seen in only 5 patients in one cohort) 1. This means:
- Focus surveillance on the primary site
- Regional nodal basins require less intensive monitoring in the adjuvant setting with clear margins
- Distant metastasis risk remains low with this treatment approach
Important Caveats
The poor differentiation status elevates this from a typical low-risk auricular SCC to a high-risk lesion, which is why the survival rates may trend toward the lower end of the quoted ranges (closer to 64% than 86%). However, the complete excision with clear margins and use of adjuvant radiotherapy substantially mitigates this risk 5.
The actual survival for your specific scenario likely falls in the 65-70% range at 5 years, given the high-risk histology balanced against optimal treatment and absence of nodal/distant disease.